Stakeholders questioned the FDA’s Commissioner’s National Priority Review Voucher (CNPV) pilot program, arguing it lacks key implementation details and may warrant pausing or cancellation. Experts cited uncertainty around candidate selection and the degree of influence from senior agency leadership, warning that the program could be duplicative relative to existing pathways. Launched last year, the voucher pilot is intended to streamline review for a subset of products tied to U.S. national priorities, including unmet medical needs and public health considerations. But critics said the fast rollout left biopharma with limited clarity and heightened perceptions of inconsistency. Some experts also pointed to the larger context of leadership churn at the agency and the distribution of vouchers already tied to expedited pathways. According to the report, 22 vouchers have been distributed across products addressing cancer, rare disease, mental health, and other U.S. health-security priorities. The debate adds to current pressure on FDA stakeholders to align accelerated-review incentives with transparent, center-led decision-making processes.